TSLA
Tesla
-- 403.840 NVDA
NVIDIA
-- 134.290 MSTR
MicroStrategy
-- 289.620 FFIE
Faraday Future Intelligent Electric Inc.
-- 2.4300 AMD
Advanced Micro Devices
-- 120.790 
Added NEWS ER
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Corp. (Nasdaq: TSBX) reported Q2 2024 financial results and business highlights. Key points include:
1. Positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer, with a 25% overall response rate and 50% disease control rate.
2. Cash position of $62.4 million, expected to fund operations into Q3 2025.
3. R&D expenses increased to $17.7 million, while G&A expenses decreased to $4.3 million.
4. Net loss for Q2 2024 was $21.3 million, slightly improved from $21.5 million in Q2 2023.
5. The company is prioritizing development in solid tumor indications, including metastatic colorectal cancer.
Turnstone Biologics Corp. (Nasdaq: TSBX) reported Q2 2024 financial results and business highlights. Key points include:
1. Positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer, with a 25% overall response rate and 50% disease control rate.
2. Cash position of $62.4 million, expected to fund operations into Q3 2025.
3. R&D expenses increased to $17.7 million, while G&A expenses decreased to $4.3 million.
4. Net loss for Q2 2024 was $21.3 million, slightly improved from $21.5 million in Q2 2023.
5. The company is prioritizing development in solid tumor indications, including metastatic colorectal cancer.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment